MedImmune Returns BiTE Compound To Micromet With An Option To Jump Back In
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners will start an all-new BiTE project and continue working on another, while Micromet takes over worldwide development of blinatumomab, for which MedImmune retains a commercialization option.
You may also be interested in...
Micromet Reacquires Full North American Rights To Blinatumomab
Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.
Micromet Reacquires Full North American Rights To Blinatumomab
Following on a March transaction in which MedImmune backed out of North American codevelopment of the antibody, full control now has been ceded to Micromet.
Taking a BiTE Out of Cancer: An Interview With Micromet CEO Christian Itin
After securing $80.5 million in financing in August and renegotiating a partnership with MedImmune, Micromet is on course to take its first BiTE antibody into pivotal trials in 2010.